Biogen (BIIB) Earns Daily Media Sentiment Score of 0.15
Media coverage about Biogen (NASDAQ:BIIB) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biogen earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.8676390991772 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s analysis:
- Biogen Inc (BIIB) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Is the Stock Safe to Invest? – Biogen Inc (NASDAQ: BIIB) – Alpha Beta Stock (alphabetastock.com)
- Stock within Investors Screening: Biogen Inc. (BIIB) – The Stocks News (press release) (thestocksnews.com)
- Buy the Bottom in Biogen Inc. Stock for a 100% Return – InvestorPlace – Investorplace.com (investorplace.com)
- Buy the Bottom in Biogen Inc. Stock for a 100% Return – Nasdaq (nasdaq.com)
Shares of BIIB stock traded down $2.39 during midday trading on Wednesday, hitting $277.29. The company had a trading volume of 1,251,290 shares, compared to its average volume of 1,637,281. The company has a quick ratio of 2.07, a current ratio of 2.34 and a debt-to-equity ratio of 0.47. The firm has a market cap of $58,892.71, a PE ratio of 23.26, a price-to-earnings-growth ratio of 1.53 and a beta of 0.90. Biogen has a twelve month low of $244.28 and a twelve month high of $370.57.
Several analysts recently commented on BIIB shares. Piper Jaffray Companies restated a “buy” rating and issued a $390.00 target price on shares of Biogen in a research report on Monday, December 18th. Nomura raised their target price on Biogen from $355.00 to $420.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Royal Bank of Canada restated a “hold” rating and issued a $321.00 target price on shares of Biogen in a research report on Tuesday, December 5th. Credit Suisse Group upgraded Biogen from a “neutral” rating to an “outperform” rating and raised their target price for the company from $321.00 to $385.00 in a research report on Wednesday, December 20th. Finally, Mizuho set a $400.00 price target on Biogen and gave the company a “buy” rating in a research report on Thursday, January 18th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and twenty-two have given a buy rating to the company’s stock. Biogen presently has an average rating of “Buy” and an average price target of $370.07.
In other news, EVP Alfred Sandrock sold 259 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $290.83, for a total value of $75,324.97. Following the completion of the sale, the executive vice president now owns 6,553 shares of the company’s stock, valued at $1,905,808.99. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert W. Pangia sold 5,832 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total value of $1,922,518.80. Following the completion of the sale, the director now directly owns 23,539 shares of the company’s stock, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. Insiders sold a total of 8,128 shares of company stock worth $2,601,512 over the last 90 days. Insiders own 0.25% of the company’s stock.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.